Published 11/06/2009 by HIV and Hepatitis.com
Experimental HCV Protease Inhibitor BI 201335 Demonstrates Promising Results in Combination with Pegylated Interferon and Ribavirin
SUMMARY: The experimental hepatitis C virus (HCV) protease inhibitor BI 201335, in combination with pegylated interferon plus ribavirin, demonstrated rapid, potent antiviral activity with a majority of patients achieving virological responses at weeks...
Share this
There are no more reports on this story yet.